
FDA authorizes another COVID-19 at-home test
Fox News
The U.S. Food and Drug Administration (FDA) announced Monday that it had issued an emergency use authorization for the ACON Laboratories Flowflex COVID-19 Home Test.
The agency said that the authorization is expected to double rapid at-home testing capacity over the next several weeks and that by the end of the year, ACON expects to produce more than 100 million tests per month and potentially 200 million tests per month by February 2022.
"This action highlights our continued commitment to increasing the availability of appropriately accurate and reliable OTC tests to meet public health needs and increase access to testing for consumers," Jeffrey E. Shuren, director of FDA’s Center for Devices and Radiological Health, said in a statement.
More Related News